Buchumschlag

Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon

Malaria is still one of the major public health threats in sub-Saharan Africa. An effective vaccine could be a sustainable control measure that can be integrated into existing health infrastructures. The malaria vaccine candidate GMZ2 is a recombinant fusion protein of conserved parts of Plasmodium...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Mordmüller, Benjamin Gottlieb (VerfasserIn) , Szywon, Katja (VerfasserIn) , Greutelaers, Benedikt (VerfasserIn) , Esen, Meral (VerfasserIn) , Mewono, Ludovic (VerfasserIn) , Treut, Carolin (VerfasserIn) , Mürbeth, Raymund E. (VerfasserIn) , Chilengi, Roma (VerfasserIn) , Noor, Ramadhani (VerfasserIn) , Kilama, Wen L. (VerfasserIn) , Imoukhuede, Egeruan B. (VerfasserIn) , Imbault, Nathalie (VerfasserIn) , Leroy, Odile (VerfasserIn) , Theisen, Michael (VerfasserIn) , Jepsen, Søren (VerfasserIn) , Milligan, Paul (VerfasserIn) , Fendel, Rolf (VerfasserIn) , Kremsner, Peter G. (VerfasserIn) , Issifou, Saadou (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 7 August 2010
In: Vaccine
Year: 2010, Jahrgang: 28, Heft: 41, Pages: 6698-6703
ISSN:1873-2518
DOI:10.1016/j.vaccine.2010.07.085
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.vaccine.2010.07.085
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0264410X10011072
Volltext
Verfasserangaben:Benjamin Mordmüller, Katja Szywon, Benedikt Greutelaers, Meral Esen, Ludovic Mewono, Carolin Treut, Raymund E. Mürbeth, Roma Chilengi, Ramadhani Noor, Wen L. Kilama, Egeruan Babatunde Imoukhuede, Nathalie Imbault, Odile Leroy, Michael Theisen, Søren Jepsen, Paul Milligan, Rolf Fendel, Peter G. Kremsner, Saadou Issifou
Beschreibung
Zusammenfassung:Malaria is still one of the major public health threats in sub-Saharan Africa. An effective vaccine could be a sustainable control measure that can be integrated into existing health infrastructures. The malaria vaccine candidate GMZ2 is a recombinant fusion protein of conserved parts of Plasmodium falciparum Glutamate Rich Protein and Merozoite Surface Protein 3 adjuvanted with aluminium hydroxide. GMZ2 is immunogenic and well tolerated in malaria-naive adults from Germany. To assess safety and immunogenicity in malaria-exposed individuals, 40 adults from Lambaréné, Gabon were randomly assigned to receive either 100μg GMZ2 or a rabies control vaccine three times in monthly intervals. Both vaccines were well tolerated. One month after a full course of vaccination, GMZ2-vaccinated individuals had 1.4-fold (95% confidence interval: [1.1, 1.7]) higher baseline-corrected anti-GMZ2 antibody levels and more GMZ2-specific memory B-cells compared to the rabies group (p=0.039), despite a high prevalence of GMZ2-specific immune reactivity due to previous intense exposure to P. falciparum.
Beschreibung:Gesehen am 04.05.2023
Beschreibung:Online Resource
ISSN:1873-2518
DOI:10.1016/j.vaccine.2010.07.085

Ähnliche Einträge